Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab plus capecitabine in platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal adenocarcinoma
ChiCTR2000035113Phase 2Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and capecitabine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal adenocarcinoma (PPC), sponsored by Mianyang Central Hospital. Primary endpoint: objective response rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sintilimabcapecitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on ChiCTR2000035113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035113.